Literature DB >> 6256054

Correlation of estrogen and progesterone receptors with histologic differentiation in mammary carcinoma.

K S McCarty, T K Barton, B F Fetter, B H Woodard, J A Mossler, W Reeves, J Daly, W E Wilkinson, K S McCarty.   

Abstract

Using a modification of the histologic grading system of the NSABP, we observed a trend towards higher levels of estrogen (E2R) and progesterone receptor (PR) content in well (grade I) and moderately (grade II) differentiated mammary carcinomas. This relationship between receptor content and histologic grade is enhanced by considering estrogen and progesterone receptor simultaneously. The rank correlation between the quantitative levels of E2R and PR was 0.74 among histologic grade I tumors and 0.64 among histologic grade II tumors. Among the grade III carcinomas, the majority of tumors displayed either a paucity of measurable receptor or a divergence between levels of estrogen versus progesterone receptor (r = 0.19). The use of ultrastructural evaluation of features of differentiation is discussed in the evaluation of grade III tumors and in the evaluation of specific histologic types of mammary carcinoma.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6256054     DOI: 10.1002/1097-0142(19801215)46:12+<2851::aid-cncr2820461424>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  22 in total

1.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

2.  A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.

Authors:  Wenle Xia; Sarah Bacus; Priti Hegde; Intisar Husain; Jay Strum; Leihua Liu; Georgina Paulazzo; Ljuba Lyass; Patricia Trusk; Jason Hill; Jennifer Harris; Neil L Spector
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

3.  Immunohistochemical versus biochemical estrogen-receptor and progesterone-receptor analysis: correlation with histological parameters.

Authors:  M Helle; M Helin; J Isola; H Helin
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

4.  Quantitative histopathology in lymph node-negative breast cancer. Prognostic significance of mitotic counts.

Authors:  M Ladekarl; V Jensen
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

5.  Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive.

Authors:  W Domagala; M Markiewski; R Kubiak; J Bartkowiak; M Osborn
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

6.  Mucinous Cystadenocarcinoma of the Breast with Estrogen Receptor Expression: A Case Report and Review of the Literature.

Authors:  Sema Rakıcı; Güzin Gönüllü; S Bilge Gürsel; Levent Yıldız; I Koray Bayrak; Idris Yücel
Journal:  Case Rep Oncol       Date:  2009-11-14

7.  Oestrogen receptors in human breast cancer. Problems of correlation with histopathological features.

Authors:  H S Poulsen; L Ozzello; J Andersen
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982

8.  Akt2 inhibition enables the forkhead transcription factor FoxO3a to have a repressive role in estrogen receptor alpha transcriptional activity in breast cancer cells.

Authors:  Catia Morelli; Marilena Lanzino; Cecilia Garofalo; Pamela Maris; Elvira Brunelli; Ivan Casaburi; Stefania Catalano; Rosalinda Bruno; Diego Sisci; Sebastiano Andò
Journal:  Mol Cell Biol       Date:  2009-11-23       Impact factor: 4.272

9.  Oestrogen and progesterone receptor content and the distribution of histological grade in breast cancer.

Authors:  S Thoresen; T Thorsen; M Tangen; F Hartveit
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

10.  Prognostic value of estrogen receptors determined by radiochemical vs. histochemical methods in breast cancer.

Authors:  P Sismondi; V Aimone; F Genta; G Voglino; F Deltetto; G Giardina; G Botta; B Ghiringhello; M P Mano; P Zola
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.